tbuckley/cabot-search huggingface dataset:
Diseases of the Colon and Rectum, Philadelphia
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Granulocyte/macrophage–colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects
Authors: Kanji Uchida, Koh Nakata, Takuji Suzuki, Maurizio Luisetti, Masato Watanabe, Diana E. Koch, Carrie A. Stevens, David C. Beck, Lee A. Denson, Brenna C. Carey, Naoto Keicho, Jeffrey P. Krischer, Yoshitsugu Yamada, Bruce C. Trapnell
Journal: Blood (2008)
Correction: Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter’s syndrome: therapeutic implications
Authors: Francesca Arruga, Valeria Bracciamà, Nicoletta Vitale, Tiziana Vaisitti, Katiuscia Gizzi, Alison Yeomans, Marta Coscia, Giovanni D’Arena, Gianluca Gaidano, John N. Allan, Richard R. Furman, Graham Packham, Francesco Forconi, Silvia Deaglio
Journal: Leukemia (2019)
National Cancer Institute Monograph 39, December 1973 “Conference on the Use of BCG in Therapy of Cancer”
Journal: JNCI Journal of the National Cancer Institute (1974)

National Cancer Institute Monograph 39, December 1973 “Conference on the Use of BCG in Therapy of Cancer” Get access JNCI: Journal of the National Cancer Institute, Volume 52, Issue 5, May 1974, Page 1679, https://doi.org/10.1093/jnci/52.5.1679-f Published: 01 May 1974
Thrombolytic Therapy
Authors: Jan Koch-Weser, G. V. R. K. Sharma, Giuseppe Cella, Alfred F. Parisi, Arthur A. Sasahara
Journal: New England Journal of Medicine (1982)

IN the continuing search for new and improved methods of treating thromboembolic diseases, the concept of an agent to dissolve clots has always been attractive. After the efficacy of heparin in venous thromboembolism was established by Barritt and Jordan,1 many physicians regarded its use as definitive, but in reality its action was only preventive. What was needed was an agent that would act on the morbid event directly — i.e., that would dissolve thromboemboli in pulmonary embolism. By restoring pulmonary vascular space, relieving pulmonary hypertension, and recompensating right ventricular function, such therapy could minimize morbidity and perhaps decrease mortality, particularly . . .
THE PROBLEM OF THE AGING SKIN
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
“Spirometric reference values in a large Middle Eastern population”. M. Golshan, M. Nematbakhsh, B. Amra, R.O. Crapo.<i>Eur Respir J</i>2003; 22: 529–534.
Journal: European Respiratory Journal (2004)

Unfortunately, there were some typographical errors in tables 2 and 3 as published.In table 2, the FEV1/FVC %, lower limit of normal should have read 0.
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment
Authors: Sara Serra, Davide Brusa, Tiziana Vaisitti, Roberta Buonincontri, Valentina Audrito, Marta Coscia, Davide Rossi, Erica B. Bhavsar, Richard R. Furman, Gianluca Gaidano, Silvia Deaglio
Journal: Blood (2015)
Cigarette smoking as a confounder of the relationship between relative weight and long-term mortality. The Framingham Heart Study
Authors: R. J. Garrison
Journal: JAMA (1983)

Cigarette smoking is a potential confounder of the relationship between obesity and mortality, and statistical control for this factor requires careful consideration. Framingham Heart Study subjects were weighed, their stature measured, and cigarette smoking histories obtained at the first biennial examination starting in 1949. Of men under desirable weight (Metropolitan relative weight [MRW], &lt;100%), more than 80% were smokers, while only about 55% of the extremely overweight men were cigarette smokers. When age-, smoking-, and MRW-specific mortalities for 26 years of follow-up were calculated in these men, it was found that smokers had higher mortality than nonsmokers but that in the smokers and nonsmokers, minimum mortalities occurred for subjects who were initially in the "desirable weight" group (MRW, 100% to 109%). Among cigarette smokers, lean men (MRW, &lt;100%) experienced considerably elevated mortality, often higher than that in all but the most overweight cigarette smokers. These findings suggest that elevated mortality in low-weight American men results from the mortality risks associated with cigarette smoking and demonstrates the need for controlling for cigarette smoking when considering the relationship between relative weight and mortality. Furthermore, the concept of "desirable weight" developed by the Metropolitan Life Insurance Co in 1959 and subsequently distributed in tabular form is validated by this long-term study. Thus, even those men who were near the average weight (about 20% above "desirable weight") showed appreciably elevated mortality. This finding is contrary to the widely held view that moderate overweight carries no increased risk. (<i>JAMA</i>1983;249:2199-2203)
New drugs against tuberculosis.
Journal: BMJ (1967)

Ascites in Africa-Nwokolo MDAJRNA 37tinned foods, and relying as much as possible on a diet made up of fruits, sugar, boiled rice, and fresh vegetables.A simple diuretic such as hydrochlorothiazide 50 mg.b.d.should be supplemented in resistant cases with spironolactone 25 mg.four times daily; potassium supplements such as potas- sium chloride 15 g.t.d.s. are usually required to prevent hypo- kalaemia.In addition to the measures mentioned above, digoxin may be required in cardiac disease.In the nephrotic syndrome steroids are sometimes effective.A high protein diet-100 g. of protein a day-is required in mal- nutrition, nephrotic syndrome (without azotaemia), and in hepatic cirrhosis (provided signs of hepatic precoma are absent).Vitamin supplements are also useful in malnutrition and states of suspected undernutrition.Alcohol is forbidden in all patients with hepatic cirrhosis.
Hypothalamic hypopituitarism presenting as galactorrhea-amenorrhea
Authors: D. Streja
Journal: JAMA (1978)

A young woman with secondary amenorrhea was also found to have a deficiency of growth hormone. Functional deficiency of adrenocorticotropic and thyroid stimulating hormones, and probably prolactin-inhibiting hormone, developed subsequently. No evidence of a mass lesion in the hypothalamic pituitary axis was found. She failed to respond to any pharmacologic agent believed to act functionally at a suprapituitary level, but responded to all stimuli believed to act directly on the pituitary. This progressive failure of the endocrine hypothalamus may be an extension of the idiopathic hypopituitarism syndrome found in children. (<i>JAMA</i>239:1783-1785, 1978)
Taking on the fat of the land: cholesterol and health
Authors: L. Grouse
Journal: JAMA (1986)

As studies continue to document the substantial health benefits of lowering serum cholesterol levels,<sup>1</sup>medical and public health organizations are advocating an aggressive role for physicians in treating patients with hypercholesterolemia and preventing it in the population at large.<sup>2</sup>Still, even with the strong pathological and epidemiologic evidence of the crucial role of hypercholesterolemia in atherogenesis, only about 30% of physicians believe its control is as important as the control of hypertension or smoking.<sup>3</sup>New national survey data (Basil Rifkind, MD, unpublished data, October 1986) suggest that both physicians and patients underestimate the health risk that hypercholesterolemia poses. This issue ofThe Journalattempts to assist physicians in the diagnosis and treatment of hypercholesterolemia by presenting authoritative data on its many clinical dimensions. Because the National Institutes of Health have taken a leading role in funding key clinical and basic scientific research in hypercholesterolemia, it is appropriate
New Therapy Could Reduce Injections for Asthma
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply
Authors: J.M. Haigh, I. Kanfer, E. Meyer, E. Smith
Journal: British Journal of Dermatology (1986)

Journal Article Reply Get access J.M. Haigh, J.M. Haigh School of Pharmaceutical Sciences, Rhodes University, Grahamstown, 6140 South Africa Search for other works by this author on: Oxford Academic Google Scholar I. Kanfer, I. Kanfer School of Pharmaceutical Sciences, Rhodes University, Grahamstown, 6140 South Africa Search for other works by this author on: Oxford Academic Google Scholar E. Meyer, E. Meyer School of Pharmaceutical Sciences, Rhodes University, Grahamstown, 6140 South Africa Search for other works by this author on: Oxford Academic Google Scholar E. Smith E. Smith School of Pharmaceutical Sciences, Rhodes University, Grahamstown, 6140 South Africa Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 114, Issue 5, 1 May 1986, Pages 637–638, https://doi.org/10.1111/j.1365-2133.1986.tb04076.x Published: 01 May 1986
Bromocriptine reduces pituitary tumor size and hypersection. Requiem for pituitary surgery?
Authors: R. F. Spark
Journal: JAMA (1982)

Twelve patients with pituitary tumor whose prior treatment included surgery and radiotherapy in four, surgery alone in four, radiotherapy alone in one, and none in three were studied. Nine had hyperprolactinemia, two had elevated serum growth hormones, and one had no pituitary hormone excess. Visual field defects were present in six. All had pituitary-gonadal insufficiency manifested as impotence or amenorrhea. All were treated with bromocriptine, 7.5 to 25 mg daily, and followed up for eight to 27 ([unk] 15) months. Serum prolactin levels decreased to normal in seven of nine patients. Serum growth hormone values were normalized in both acromegalics. When hormone levels were reduced to normal, pituitary tumor size decreased. Vision was restored to normal in five of six patients, including one patient with pituitary tumor but no pituitary hormone excess. Bromocriptine corrects the physiological defects associated with pituitary tumors that have been incompletely treated with surgery, radiotherapy, or both and may be a useful primary treatment for patients with pituitary tumors. (<i>JAMA</i>1982;247:311-316)
COMMENDABLE SOCIETY WORK.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Interventional Radiology
Authors: Anthony F. Lalli
Journal: JAMA (1982)

This is a large book of 806 pages that measure 21 cm × 28 cm. The book is well and lavishly illustrated and is also well indexed. The six sections include 61 chapters devoted to equipment and methods, blood flow alterations including embolization and angioplasties, renal procedures such as cyst punctures, nephrostomies, and stone dissolutions, biliary and abdominal abscess drainages, percutaneous lung biopsies, neuroradiological embolizations, breast mass localizations, bone biopsies, and reduction of intussusceptions by bariumenema. The radiologist with limited experience who wishes to embark on these procedures will receive excellent guidance from this book and will feel somewhat reinforced when he attempts for the first time to apply drugs such as tolazoline, remove an intravascular foreign body, or perform a percutaneous nephrostomy late one evening on a patient with obvious signs of severe pyohydronephrosis. The book has been well proofread, a commendable aspect in this day of inadequate attention to printed errors.
Five-year findings of the hypertension detection and follow-up program. II. Mortality by race-sex and age. Hypertension Detection and Follow-up Program Cooperative Group
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In This Issue
Journal: Journal of Clinical Investigation (2010)

Symptoms of Noonan syndrome ameliorated in miceNoonan syndrome (NS) is a relatively common autosomal dominant genetic disorder that is characterized by short stature, unique facial features, and congenital heart disease.Approximately 10%-15% of affected individuals have mutations in son of sevenless 1 (SOS1), which encodes a guanine nucleotide exchange factor for RAS and RAC.As with all other known NS-associated genetic mutations, SOS1 mutations lead to increased RAS/ MAPK pathway signaling.In this issue (4353-4365), Chen and colleagues report the generation of a mouse model of NS caused by SOS1 mutations - knockin mice expressing the NS-associated Sos1E846K gain-of-function mutation.Homozygosity for the mutation led to multiple cardiac defects, similar to those in humans with NS, and substantial embryonic lethality.As in individuals with NS, heterozygosity for the mutation caused cardiac defects, short stature, and facial dysmorphia.In addition to Ras/MAPK pathway activation in hearts from mutant mice, Rac and Stat3 were activated.Importantly, prenatal treatment with a smallmolecule MAPK kinase inhibitor reduced the embryonic lethality of homozygosity for this mutation and ameliorated the cardiac defects.The authors therefore suggest that targeting this pathway might be of benefit to individuals with NS.
Disparities in Cholesterol Screening in the United States. Falling Short of a National Health Objective
Authors: David W Brown, Wayne H Giles, Kurt J Greenlund, Janet B Croft
Journal: Circulation (2001)

P40 Objectives: To determine whether the Year 2000 national health objective for cholesterol screening was attained and to identify disparities in cholesterol screening across racial or ethnic and socioeconomic groups. Methods: Using data from the 1999 Behavioral Risk Factor Surveillance System, we estimated the proportion of adults aged ≥20 years who were screened for high blood cholesterol within the preceding 5 years. Results: Overall, an estimated 70.8% of the US population was screened for cholesterol, falling short of the Year 2000 objective of 75%. Screening prevalence was lowest at ages 20-44 years (58.2%) in contrast to ages 45-64 years (81.9%) and ages ≥65 years (87.1%). Screening prevalence was also lowest among Hispanics, especially Hispanic men. The likelihood of screening decreased with decreasing income level (p&lt;0.05) and persons with health insurance were 1.6 times more likely to have been screened during the past 5 years than adults with no insurance (p&lt;0.05). Conclusions: Significant disparities in cholesterol screening exist across age, sex, racial or ethnic, and socioeconomic groups in the United States. As we look to attain the objectives of Healthy People 2010, state and local health officials and policy makers should be aware of these disparities in order to design and target effective cholesterol screening programs and cardiovascular disease prevention programs to those most in need.
PALESTINE
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Poster Session 1: Donor Factors and Allocation
Authors: Berna Gürsel, Fulya Gunsar, Funda Yilmaz, Zeki Karasu, Galip Ersoz, Janske Reiling, David Lockwood, Andrew Simpson, Catherine Campbell, Kim Bridle, Nishreen Santrampur- Wala, Laurence Britton, Darrell Crawford, Cornelis Dejong, Jonathan Fawcett, Kilian Friedrich, Christian Rupp, Andreas Wannhoff, Wolfgang Stremmel, Daniel Gotthardt
Journal: Hepatology (2014)

erbations during prednisone tapering.The patients with >3 exacerbations were younger than those with <3 exacerbations (56,6+16 vs 37+15, p:0,02).ALT normalized within 6 months in 16 (69,6%) TD patients and in 46 (88,5%) GR patients (p<0,046).Maintenance dose of prednisolon was higher in TD patients (8,05±4,8 vs 4,98±2,2 mg/day; p. 0,016) as expected.Duration of prednisone treatment was longer in TD patients (44±29 vs 27±22 months; p:0,013).Side effects (29% vs 8,3%) and dose reductions (43% vs 20%) of azathioprine were more common in TD patients (p<0,05).ALT, AST, GGT, globulin levels were higher in TD patients comparing to GR patients at 6th month of therapy (p<0,05).Anti smooth muscle antibody (ASMA) positivity was more common in TD patients with higher number of exacerbations (%80 vs %27,8; p:0,056).Liver disease progression was observed in 9 TD (36%) patients and in 8 (14%) GR patients during a median of 27 (6-168) months of follow up (p:0.027).Conclusions.Treatment dependent patients use higher dose of prednisolon with longer duration.Their biochemical remission is achieved later comparing to GR patients'.Azathioprine side effects or intolerance are important issues for treatment dependency.As TD patients have more progressive liver disease, other immmunosupresive drugs such as mycophenolate mofetil or cyclosporine should be tried.